UY28421A1 - Sistemas semi-sólidos que contienen derivados de azetidina - Google Patents

Sistemas semi-sólidos que contienen derivados de azetidina

Info

Publication number
UY28421A1
UY28421A1 UY28421A UY28421A UY28421A1 UY 28421 A1 UY28421 A1 UY 28421A1 UY 28421 A UY28421 A UY 28421A UY 28421 A UY28421 A UY 28421A UY 28421 A1 UY28421 A1 UY 28421A1
Authority
UY
Uruguay
Prior art keywords
semi
azetidine
systems containing
solid systems
containing derivatives
Prior art date
Application number
UY28421A
Other languages
English (en)
Inventor
Peracchia Maria-Teresa
Cote Sophie
Bobineau Valerie
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of UY28421A1 publication Critical patent/UY28421A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Sistemas semi-sólidos que contienen derivados de azetidina. La presente invención se refiere a nuevas formulaciones de derivados de azetidina para administración oral.
UY28421A 2003-07-18 2004-07-16 Sistemas semi-sólidos que contienen derivados de azetidina UY28421A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03291796A EP1498122A1 (en) 2003-07-18 2003-07-18 Semi-solid systems containing azetidine derivatives

Publications (1)

Publication Number Publication Date
UY28421A1 true UY28421A1 (es) 2005-02-28

Family

ID=33462259

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28421A UY28421A1 (es) 2003-07-18 2004-07-16 Sistemas semi-sólidos que contienen derivados de azetidina

Country Status (30)

Country Link
US (2) US20050026898A1 (es)
EP (2) EP1498122A1 (es)
JP (1) JP2009513560A (es)
KR (1) KR20060040691A (es)
CN (1) CN1822831A (es)
AR (1) AR045997A1 (es)
AU (1) AU2004262498B2 (es)
BR (1) BRPI0412737A (es)
CA (1) CA2532669A1 (es)
CR (1) CR8179A (es)
EC (1) ECSP066292A (es)
GT (1) GT200400135A (es)
HR (1) HRP20060022A2 (es)
IL (1) IL173111A0 (es)
MA (1) MA27922A1 (es)
MX (1) MXPA06000483A (es)
MY (1) MY142077A (es)
NO (1) NO20060509L (es)
OA (1) OA13191A (es)
PA (1) PA8606701A1 (es)
PE (1) PE20050287A1 (es)
RS (1) RS20060016A (es)
RU (1) RU2343915C2 (es)
SG (1) SG144141A1 (es)
TN (1) TNSN06013A1 (es)
TW (1) TW200522945A (es)
UA (1) UA80633C2 (es)
UY (1) UY28421A1 (es)
WO (1) WO2005013973A1 (es)
ZA (1) ZA200600490B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007123366A (ru) * 2004-11-24 2008-12-27 Мерк Энд Ко. Жидкие и полутвердые фармацевтические препаративные формы для перорального введения замещенного амида
FR2923719B1 (fr) * 2007-11-15 2009-11-20 Sanofi Aventis Compositions pharmaceutiques a base de derives d'azetidine
CN101926757B (zh) * 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法
ES2718090T3 (es) * 2010-11-08 2019-06-27 Cadila Pharmaceuticals Ltd Composición farmacéutica de taxoides
EP3086777A1 (en) * 2013-12-23 2016-11-02 Johnson & Johnson Consumer Inc. Racecadotril compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11505257A (ja) * 1995-05-19 1999-05-18 アボツト・ラボラトリーズ 親油性薬物の自己乳化性製剤
CA2302735A1 (en) * 1998-07-14 2000-01-27 Em Industries, Inc. Microdisperse drug delivery systems
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6355631B1 (en) * 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
FR2814678B1 (fr) * 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
FR2829027A1 (fr) * 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson
FR2833842B1 (fr) * 2001-12-21 2004-02-13 Aventis Pharma Sa Compositions pharmaceutiques a base de derives d'azetidine
EP1498123A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Emulsifying systems containing azetidine derivatives

Also Published As

Publication number Publication date
MY142077A (en) 2010-08-30
AU2004262498B2 (en) 2009-01-22
PE20050287A1 (es) 2005-06-13
EP1648442A1 (en) 2006-04-26
GT200400135A (es) 2005-08-25
BRPI0412737A (pt) 2006-09-26
AU2004262498A2 (en) 2005-02-17
IL173111A0 (en) 2006-06-11
JP2009513560A (ja) 2009-04-02
HRP20060022A2 (en) 2006-02-28
EP1498122A1 (en) 2005-01-19
US20080293686A1 (en) 2008-11-27
AR045997A1 (es) 2005-11-23
MXPA06000483A (es) 2006-04-05
NO20060509L (no) 2006-01-31
RU2343915C2 (ru) 2009-01-20
PA8606701A1 (es) 2005-02-04
AU2004262498A1 (en) 2005-02-17
US20050026898A1 (en) 2005-02-03
ZA200600490B (en) 2007-05-30
TW200522945A (en) 2005-07-16
RU2006105011A (ru) 2006-06-10
WO2005013973A1 (en) 2005-02-17
OA13191A (en) 2006-12-13
CA2532669A1 (en) 2005-02-17
RS20060016A (en) 2008-06-05
CN1822831A (zh) 2006-08-23
TNSN06013A1 (en) 2007-10-03
UA80633C2 (en) 2007-10-10
ECSP066292A (es) 2006-10-25
KR20060040691A (ko) 2006-05-10
MA27922A1 (fr) 2006-06-01
CR8179A (es) 2006-09-22
SG144141A1 (en) 2008-07-29

Similar Documents

Publication Publication Date Title
ECSP066291A (es) Sistemas emulsionantes que contienen derivados de azetidina
HN2003000408A (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos.
CO5590918A2 (es) Formulaciones
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
UY28215A1 (es) Quinazolinas utiles como moduladores de canales iónicos
HN2002000300A (es) Nuevos derivados de piperazina
ECSP066860A (es) Formulaciones de matriz oral que comprenden licarbazepina
BRPI0408895A (pt) formulações de cladribina para administração oral e transmucosal aperfeiçoada
ECSP066292A (es) Sistemas semi-sólidos que contienen derivados de azetidina
MXPA06000636A (es) Formulaciones semi-solidas para la administracion oral de taxoides.
HN2001000021A (es) Nuevos derivados de amidas heterociclicas
HN2002000082A (es) Composiciones que contienen imidazotriazinona para administracion nasal
ECSP066441A (es) ?15-d-homoesteroides que tienen un efecto androgénico
HN2002000084A (es) Fenil - heterociclil - eteres
HN2002000331A (es) Composiciones farmaceuticas de 5,7,14-triazatetra-ciclo (10.3.1.02,11.04,9)-hexadeca-2(11) 3,5,7,9-pentaeno
HN2002000049A (es) Nuevos compuestos antiinflamatorios de triazolopiridinas
HN1998003740A (es) Composiciones farmaceuticas que contienen elet triptan emilsulfato
HN2002000099A (es) Derivadposs de cromano 2,6 sustituidos utiles como agonistas adrenoreceptores beta - 3
UY27823A1 (es) Nueva formulación para la administración parenteral de un bloqueante del canal del na